C5L2 – an Anti-inflammatory Molecule or a Receptor for Acylation Stimulating Protein (C3a-desArg)?

  • Kay Johswich
  • Andreas Klos
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 598)


Human Skin Fibroblast Triglyceride Synthesis Culture Skin Fibroblast Acylation Stimulate Protein Triacylglycerol Synthesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amatruda, T. T., III, Gerard, N. P., Gerard, C., and Simon, M. I. (1993). “Specific interactions of chemoattractant factor receptors with G- proteins.” J.Biol.Chem. 268:10139-10144.PubMedGoogle Scholar
  2. Ames, R. S., Li, Y., Sarau, H. M., Nuthulaganti, P., Foley, J. J., Ellis, C., Zeng, Z., Su, K., Jurewicz, A. J., Hertzberg, R. P., Bergsma, D. J., and Kumar, C. (1996). “Molecular cloning and characterization of the human anaphylatoxin C3a receptor.” J.Biol.Chem. 271:20231-20234.PubMedCrossRefGoogle Scholar
  3. Arumugam, T. V., Shiels, I. A., Woodruff, T. M., Granger, D. N., and Taylor, S. M. (2004). “The role of the complement system in ischemia-reperfusion injury.” Shock. 21:401-409.PubMedCrossRefGoogle Scholar
  4. Baldo, A., Sniderman, A. D., St Luce, S., Avramoglu, R. K., Maslowska, M., Hoang, B., Monge, J. C., Bell, A., Mulay, S., and Cianflone, K. (1993). “The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis.” J.Clin.Invest. 92:1543-1547.PubMedGoogle Scholar
  5. Baldo, A., Sniderman, A. D., St Luce, S., Zhang, X. J., and Cianflone, K. (1995). “Signal transduction pathway of acylation stimulating protein: involvement of protein kinase C.” J.Lipid Res. 36:1415-1426.PubMedGoogle Scholar
  6. Bao, L., Gerard, N. P., Eddy, R. L., Jr., Shows, T. B., and Gerard, C. (1992). “Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19.” Genomics. 13:437-440.PubMedCrossRefGoogle Scholar
  7. Bock, D., Martin, U., Gartner, S., Rheinheimer, C., Raffetseder, U., Arseniev, L., Barker, M. D., Monk, P. N., Bautsch, W., Kohl, J., and Klos, A. (1997). “The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization.” Eur.J.Immunol. 27:1522-1529.PubMedCrossRefGoogle Scholar
  8. Boulay, F., Mery, L., Tardif, M., Brouchon, L., and Vignais, P. (1991). “Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells.” Biochemistry. 30:2993-2999.PubMedCrossRefGoogle Scholar
  9. Buhl, A. M., Avdi, N., Worthen, G. S., and Johnson, G. L. (1994). “Mapping of the C5a receptor signal transduction network in human neutrophils.” Proc.Natl.Acad.Sci.U.S.A. 91:9190-9194.PubMedCrossRefGoogle Scholar
  10. Cain, S. A. and Monk, P. N. (2002). “The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74).” J.Biol.Chem. 277:7165-7169.PubMedCrossRefGoogle Scholar
  11. Chaudhuri, A., Nielsen, S., Elkjaer, M. L., Zbrzezna, V., Fang, F., and Pogo, A. O. (1997). “Detection of Duffy antigen in the plasma membranes and caveolae of vascular endothelial and epithelial cells of nonerythroid organs.” Blood. 89:701-712.PubMedGoogle Scholar
  12. Chenoweth, D. E. and Goodman, M. G. (1983). “The C5a receptor of neutrophils and macrophages.” Agents Actions Suppl. 12:252-273.PubMedGoogle Scholar
  13. Chenoweth, D. E. and Hugli, T. E. (1978). “Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes.” Proc.Natl.Acad.Sci.U.S.A. 75:3943-3947.PubMedCrossRefGoogle Scholar
  14. Cianflone, K., Kalant, D., Marliss, E. B., Gougeon, R., and Sniderman, A. D. (1995). “Response of plasma ASP to a prolonged fast.” Int.J.Obes.Relat Metab Disord. 19:604-609.PubMedGoogle Scholar
  15. Cianflone, K., Kwiterovich, P. O., Walsh, M., Forse, A., Rodriguez, M. A., and Sniderman, A. D. (1987). “Stimulation of fatty acid uptake and triglyceride synthesis in human cultured skin fibroblasts and adipocytes by a serum protein.” Biochem.Biophys.Res.Commun. 144:94-100.PubMedCrossRefGoogle Scholar
  16. Cianflone, K., Rodriguez, M. A., Walsh, M., Vu, H., and Sniderman, A. D. (1988). “The effect of a plasma protein fraction on lipid synthesis in cultured skin fibroblasts from normals and patients with hyperapobetalipoproteinemia.” Clin.Invest Med. 11:99-107.PubMedGoogle Scholar
  17. Cianflone, K., Roncari, D. A., Maslowska, M., Baldo, A., Forden, J., and Sniderman, A. D. (1994). “Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis.” Biochemistry. 33:9489-9495.PubMedCrossRefGoogle Scholar
  18. Cianflone, K., Vu, H., Walsh, M., Baldo, A., and Sniderman, A. (1989a). “Metabolic response of Acylation Stimulating Protein to an oral fat load.” J.Lipid Res. 30:1727-1733.Google Scholar
  19. Cianflone, K., Xia, Z., and Chen, L. Y. (2003). “Critical review of acylation-stimulating protein physiology in humans and rodents.” Biochim.Biophys.Acta. 1609:127-143.PubMedCrossRefGoogle Scholar
  20. Cianflone, K., Zhang, X. J., Genest, J., Jr., and Sniderman, A. (1997). “Plasma acylation-stimulating protein in coronary artery disease.” Arterioscler.Thromb.Vasc.Biol. 17:1239-1244.PubMedGoogle Scholar
  21. Cianflone, K. M., Maslowska, M. H., and Sniderman, A. D. (1990). “Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein.” J.Clin.Invest. 85:722-730.PubMedCrossRefGoogle Scholar
  22. Cianflone, K. M., Sniderman, A. D., Walsh, M. J., Vu, H. T., Gagnon, J., and Rodriguez, M. A. (1989b). “Purification and characterization of acylation stimulating protein.” J.Biol.Chem. 264:426-430.Google Scholar
  23. Comerford, I., Milasta, S., Morrow, V., Milligan, G., and Nibbs, R. (2006). “The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro.” Eur.J.Immunol. 36:1904-1916.PubMedCrossRefGoogle Scholar
  24. Cook, K. S., Min, H. Y., Johnson, D., Chaplinsky, R. J., Flier, J. S., Hunt, C. R., and Spiegelman, B. M. (1987). “Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve.” Science. 237:402-405.PubMedCrossRefGoogle Scholar
  25. Crass, T., Raffetseder, U., Martin, U., Grove, M., Klos, A., Kohl, J., and Bautsch, W. (1996). “Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells.” Eur.J.Immunol. 26:1944-1950.PubMedCrossRefGoogle Scholar
  26. Farkas, I., Baranyi, L., Takahashi, M., Fukuda, A., Liposits, Z., Yamamoto, T., and Okada, H. (1998). “A neuronal C5a receptor and an associated apoptotic signal transduction pathway.” J.Physiol (Lond). 507 ( Pt 3):679-687.CrossRefGoogle Scholar
  27. Farzan, M., Schnitzler, C. E., Vasilieva, N., Leung, D., Kuhn, J., Gerard, C., Gerard, N. P., and Choe, H. (2001). “Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor.” J.Exp.Med. 193:1059-1066.PubMedCrossRefGoogle Scholar
  28. Fayyazi, A., Scheel, O., Werfel, T., Schweyer, S., Oppermann, M., Gotze, O., Radzun, H. J., and Zwirner, J. (2000). “The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells.” Immunology. 99:38-45.PubMedCrossRefGoogle Scholar
  29. Fukuoka, Y. and Hugli, T. E. (1990). “Anaphylatoxin binding and degradation by rat peritoneal mast cells. Mechanisms of degranulation and control.” J.Immunol. 145:1851-1858.PubMedGoogle Scholar
  30. Galliera, E., Jala, V. R., Trent, J. O., Bonecchi, R., Signorelli, P., Lefkowitz, R. J., Mantovani, A., Locati, M., and Haribabu, B. (2004). “beta-Arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6.” J.Biol.Chem. 279:25590-25597.PubMedCrossRefGoogle Scholar
  31. Gao, H., Neff, T. A., Guo, R. F., Speyer, C. L., Sarma, J. V., Tomlins, S., Man, Y., Riedemann, N. C., Hoesel, L. M., Younkin, E., Zetoune, F. S., and Ward, P. A. (2005). “Evidence for a functional role of the second C5a receptor C5L2.” FASEB J. 19:1003-1005.PubMedGoogle Scholar
  32. Gao, J., Choe, H., Bota, D., Wright, P. L., Gerard, C., and Gerard, N. P. (2003). “Sulfation of tyrosine 174 in the human C3a receptor is essential for binding of C3a anaphylatoxin.” J.Biol.Chem. 278:37902-37908.PubMedCrossRefGoogle Scholar
  33. Gasque, P., Singhrao, S. K., Neal, J. W., Gotze, O., and Morgan, B. P. (1997). “Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system.” Am.J.Pathol. 150:31-41.PubMedGoogle Scholar
  34. Gavrilyuk, V., Kalinin, S., Hilbush, B. S., Middlecamp, A., McGuire, S., Pelligrino, D., Weinberg, G., and Feinstein, D. L. (2005). “Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties.” J.Neurochem. 92:1140-1149.PubMedCrossRefGoogle Scholar
  35. Gerard, C., Bao, L., Orozco, O., Pearson, M., Kunz, D., and Gerard, N. P. (1992). “Structural diversity in the extracellular faces of peptidergic G- protein-coupled receptors. Molecular cloning of the mouse C5a anaphylatoxin receptor.” J.Immunol. 149:2600-2606.PubMedGoogle Scholar
  36. Gerard, N. P. and Gerard, C. (1991). “The chemotactic receptor for human C5a anaphylatoxin.” Nature. 349:614-617.PubMedCrossRefGoogle Scholar
  37. Gerard, N. P., Hodges, M. K., Drazen, J. M., Weller, P. F., and Gerard, C. (1989). “Characterization of a receptor for C5a anaphylatoxin on human eosinophils.” J.Biol.Chem. 264:1760-1766.PubMedGoogle Scholar
  38. Gerard, N. P., Lu, B., Liu, P., Craig, S., Fujiwara, Y., Okinaga, S., and Gerard, C. (2005). “An anti-inflammatory function for the complement anaphylatoxin C5a binding protein, C5L2.” J.Biol.Chem. Google Scholar
  39. Germinario, R., Sniderman, A. D., Manuel, S., Lefebvre, S. P., Baldo, A., and Cianflone, K. (1993). “Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein.” Metabolism. 42:574-580.PubMedCrossRefGoogle Scholar
  40. Gervasoni, J. E., Jr., Conrad, D. H., Hugli, T. E., Schwartz, L. B., and Ruddy, S. (1986). “Degradation of human anaphylatoxin C3a by rat peritoneal mast cells: a role for the secretory granule enzyme chymase and heparin proteoglycan.” J.Immunol. 136:285-292.PubMedGoogle Scholar
  41. Guo, R. F., Riedemann, N. C., and Ward, P. A. (2004). “Role of C5a-C5aR interaction in sepsis.” Shock. 21:1-7.PubMedCrossRefGoogle Scholar
  42. Hartmann, H., Lubbers, B., Casaretto, M., Bautsch, W., Klos, A., and Kohl, J. (1993). “Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures.” J.Immunol.Methods. 166:35-44.PubMedCrossRefGoogle Scholar
  43. Havel, P. J. (2004). “Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism.” Diabetes. 53 Suppl 1:S143-S151.PubMedCrossRefGoogle Scholar
  44. Hopken, U. E., Lu, B., Gerard, N. P., and Gerard, C. (1996). “The C5a chemoattractant receptor mediates mucosal defence to infection.” Nature. 383:86-89.PubMedCrossRefGoogle Scholar
  45. Huber-Lang, M., Sarma, J. V., Rittirsch, D., Schreiber, H., Weiss, M., Flierl, M., Younkin, E., Schneider, M., Suger-Wiedeck, H., Gebhard, F., McClintock, S. D., Neff, T., Zetoune, F., Bruckner, U., Guo, R. F., Monk, P. N., and Ward, P. A. (2005). “Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans.” J.Immunol. 174:1104-1110.PubMedGoogle Scholar
  46. Huey, R., Bloor, C. M., Kawahara, M. S., and Hugli, T. E. (1983). “Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.” Am.J.Pathol. 112:48-60.PubMedGoogle Scholar
  47. Johswich, K., Martin, M., Thalmann, J., Rheinheimer, C., Monk, P. N., and Klos, A. (2006). “Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell-lines.” J.Biol.Chem. Google Scholar
  48. Kajita, T. and Hugli, T. E. (1991). “Evidence for in vivo degradation of C3a anaphylatoxin by mast cell chymase. I. Nonspecific activation of rat peritoneal mast cells by C3ades Arg.” Am.J.Pathol. 138: 1359-1369.PubMedGoogle Scholar
  49. Kalant, D., Cain, S. A., Maslowska, M., Sniderman, A. D., Cianflone, K., and Monk, P. N. (2003). “The chemoattractant receptor-like protein, C5L2, binds C3a desArg77/acylation stimulating protein.” J.Biol.Chem. 278(13):11123-11129.PubMedCrossRefGoogle Scholar
  50. Kalant, D., Maclaren, R., Cui, W., Samanta, R., Monk, P. N., Laporte, S. A., and Cianflone, K. (2005). “C5L2 Is a Functional Receptor for Acylation-stimulating Protein.” J.Biol.Chem. 280:23936-23944.PubMedCrossRefGoogle Scholar
  51. Kildsgaard, J., Zsigmond, E., Chan, L., and Wetsel, R. A. (1999). “A critical evaluation of the putative role of C3adesArg (ASP) in lipid metabolism and hyperapobetalipoproteinemia.” Mol.Immunol. 36: 869-876.PubMedCrossRefGoogle Scholar
  52. Klos, A., Bank, S., Gietz, C., Bautsch, W., Kohl, J., Burg, M., and Kretzschmar, T. (1992). “C3a receptor on dibutyryl-cAMP-differentiated U937 cells and human neutrophils: the human C3a receptor characterized by functional responses and 125I-C3a binding.” Biochemistry. 31:11274-11282.PubMedCrossRefGoogle Scholar
  53. Kohl, J., Baelder, R., Lewkowich, I. P., Pandey, M. K., Hawlisch, H., Wang, L., Best, J., Herman, N. S., Sproles, A. A., Zwirner, J., Whitsett, J. A., Gerard, C., Sfyroera, G., Lambris, J. D., and Wills-Karp, M. (2006). “A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma.” J.Clin.Invest. 116:783-796.PubMedCrossRefGoogle Scholar
  54. Kohl, J. and Gessner, J. E. (1999). “On the role of complement and Fc gamma-receptors in the Arthus reaction.” Mol.Immunol. 36:893-903.PubMedCrossRefGoogle Scholar
  55. Kolakowski, L. F., Jr., Lu, B., Gerard, C., and Gerard, N. P. (1995). “Probing the “message:address” sites for chemoattractant binding to the C5a receptor. Mutagenesis of hydrophilic and proline residues within the transmembrane segments.” J.Biol.Chem. 270:18077-18082.PubMedCrossRefGoogle Scholar
  56. la Sala, A., Gadina, M., and Kelsall, B. L. (2005). “G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK.” J.Immunol. 175:2994-2999.PubMedGoogle Scholar
  57. Langkabel, P., Zwirner, J., and Oppermann, M. (1999). “Ligand-induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by “G protein-coupled receptor kinases.” Eur.J.Immunol. 29:3035-3046.PubMedCrossRefGoogle Scholar
  58. Laudes, I. J., Chu, J. C., Huber-Lang, M., Guo, R. F., Riedemann, N. C., Sarma, J. V., Mahdi, F., Murphy, H. S., Speyer, C., Lu, K. T., Lambris, J. D., Zetoune, F. S., and Ward, P. A. (2002). “Expression and function of C5a receptor in mouse microvascular endothelial cells.” J.Immunol. 169:5962-5970.PubMedGoogle Scholar
  59. Lee, D. K., George, S. R., Cheng, R., Nguyen, T., Liu, Y., Brown, M., Lynch, K. R., and O’Dowd, B. F. (2001). “Identification of four novel human G protein-coupled receptors expressed in the brain.” Brain Res.Mol.Brain Res. 86:13-22.PubMedCrossRefGoogle Scholar
  60. Luo, H., Chaudhuri, A., Johnson, K. R., Neote, K., Zbrzezna, V., He, Y., and Pogo, A. O. (1997). “Cloning, characterization, and mapping of a murine promiscuous chemokine receptor gene: homolog of the human Duffy gene.” Genome Res. 7:932-941.PubMedGoogle Scholar
  61. Marcil, M., Vu, H., Cui, W., Dastani, Z., Engert, J. C., Gaudet, D., Castro-Cabezas, M., Sniderman, A. D., Genest, Jr J., and Cianflone, K. (2006). “Identification of a Novel C5L2 Variant (S323I) in a French Canadian Family With Familial Combined Hyperlipemia.” Arterioscler.Thromb.Vasc.Biol. Google Scholar
  62. Marder, S. R., Chenoweth, D. E., Goldstein, I. M., and Perez, H. D. (1985). “Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg.” J.Immunol. 134:3325-3331.PubMedGoogle Scholar
  63. Martin, U., Bock, D., Arseniev, L., Tornetta, M. A., Ames, R. S., Bautsch, W., Kohl, J., Ganser, A., and Klos, A. (1997). “The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes.” J.Exp.Med. 186:199-207.PubMedCrossRefGoogle Scholar
  64. Maslowska, M., Legakis, H., Assadi, F., and Cianflone, K. (2006). “Targeting the signaling pathway of acylation stimulating protein.” J.Lipid Res. 47:643-652.PubMedCrossRefGoogle Scholar
  65. Maslowska, M., Scantlebury, T., Germinario, R., and Cianflone, K. (1997). “Acute in vitro production of acylation stimulating protein in differentiated human adipocytes.” J.Lipid Res. 38:1-11.PubMedGoogle Scholar
  66. Middleton, J., Neil, S., Wintle, J., Clark-Lewis, I., Moore, H., Lam, C., Auer, M., Hub, E., and Rot, A. (1997). “Transcytosis and surface presentation of IL-8 by venular endothelial cells.” Cell. 91:385-395.PubMedCrossRefGoogle Scholar
  67. Mukherjee, P. and Pasinetti, G. M. (2000). “The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer’s disease.” J.Neuroimmunol. 105:124-130.PubMedCrossRefGoogle Scholar
  68. Mullmann, T. J., Siegel, M. I., Egan, R. W., and Billah, M. M. (1990). “Complement C5a activation of phospholipase D in human neutrophils. A major route to the production of phosphatidates and diglycerides.” J.Immunol. 144:1901-1908.PubMedGoogle Scholar
  69. Murray, I., Kohl, J., and Cianflone, K. (1999a). “Acylation-stimulating protein (ASP): structure-function determinants of cell surface binding and triacylglycerol synthetic activity.” Biochem.J. 342 ( Pt 1): 41-48.CrossRefGoogle Scholar
  70. Murray, I., Parker, R. A., Kirchgessner, T. G., Tran, J., Zhang, Z. J., Westerlund, J., and Cianflone, K. (1997). “Functional bioactive recombinant acylation stimulating protein is distinct from C3a anaphylatoxin.” J.Lipid Res. 38:2492-2501.PubMedGoogle Scholar
  71. Murray, I., Sniderman, A. D., and Cianflone, K. (1999a). “Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice.” Am.J.Physiol. 277:E474-E480.Google Scholar
  72. Murray, I., Sniderman, A. D., and Cianflone, K. (1999b). “Mice lacking acylation stimulating protein (ASP) have delayed postprandial triglyceride clearance.” J.Lipid Res. 40:1671-1676.Google Scholar
  73. Murray, I., Sniderman, A. D., Havel, P. J., and Cianflone, K. (1999c). “Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice.” J.Biol.Chem. 274: 36219-36225.CrossRefGoogle Scholar
  74. Nibbs, R. J., Wylie, S. M., Pragnell, I. B., and Graham, G. J. (1997). “Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5.” J.Biol.Chem. 272:12495-12504.PubMedCrossRefGoogle Scholar
  75. Nibbs, R. J., Wylie, S. M., Yang, J., Landau, N. R., and Graham, G. J. (1997). “Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6.” J.Biol.Chem. 272:32078-32083.PubMedCrossRefGoogle Scholar
  76. Norgauer, J., Dobos, G., Kownatzki, E., Dahinden, C., Burger, R., Kupper, R., and Gierschik, P. (1993). “Complement fragment C3a stimulates Ca2+ influx in neutrophils via a pertussis-toxin-sensitive G protein.” Eur.J.Biochem. 217:289-294.PubMedCrossRefGoogle Scholar
  77. Ohno, M., Hirata, T., Enomoto, M., Araki, T., Ishimaru, H., and Takahashi, T. A. (2000). “A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells.” Mol.Immunol. 37:407-412.PubMedCrossRefGoogle Scholar
  78. Okinaga, S., Slattery, D., Humbles, A., Zsengeller, Z., Morteau, O., Kinrade, M. B., Brodbeck, R. M., Krause, J. E., Choe, H. R., Gerard, N. P., and Gerard, C. (2003). “C5L2, a nonsignaling C5A binding protein.” Biochemistry. 42:9406-9415.PubMedCrossRefGoogle Scholar
  79. Paral, D., Sohns, B., Crass, T., Grove, M., Kohl, J., Klos, A., and Bautsch, W. (1998). “Genomic organization of the human C3a receptor.” Eur.J.Immunol. 28:2417-2423.PubMedCrossRefGoogle Scholar
  80. Perianayagam, M. C., Balakrishnan, V. S., King, A. J., Pereira, B. J., and Jaber, B. L. (2002). “C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3- kinase-signaling pathway.” Kidney Int. 61:456-463.PubMedCrossRefGoogle Scholar
  81. Perret, J. J., Raspe, E., Vassart, G., and Parmentier, M. (1992). “Cloning and functional expression of the canine anaphylatoxin C5a receptor. Evidence for high interspecies variability.” Biochem.J. 288 (Pt 3):911-917.PubMedGoogle Scholar
  82. Ratajczak, M. Z., Reca, R., Wysoczynski, M., Kucia, M., Baran, J. T., Allendorf, D. J., Ratajczak, J., and Ross, G. D. (2004). “Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells.” Leukemia. 18:1482-1490.PubMedCrossRefGoogle Scholar
  83. Roglic, A., Prossnitz, E. R., Cavanagh, S. L., Pan, Z., Zou, A., and Ye, R. D. (1996). “cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure.” Biochim.Biophys.Acta. 1305:39-43.PubMedGoogle Scholar
  84. Rollins, T. E., Siciliano, S., Kobayashi, S., Cianciarulo, D. N., Bonilla-Argudo, V., Collier, K., and Springer, M. S. (1991). “Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex.” Proc.Natl.Acad.Sci.U.S.A. 88:971-975.PubMedCrossRefGoogle Scholar
  85. Sayah, S., Jauneau, A. C., Patte, C., Tonon, M. C., Vaudry, H., and Fontaine, M. (2003). “Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes.” Brain Res.Mol.Brain Res. 112:53-60.PubMedCrossRefGoogle Scholar
  86. Schraufstatter, I. U., Trieu, K., Sikora, L., Sriramarao, P., and DiScipio, R. (2002). “Complement c3a and c5a induce different signal transduction cascades in endothelial cells.” J.Immunol. 169:2102-2110.PubMedGoogle Scholar
  87. Settmacher, B., Bock, D., Saad, H., Gartner, S., Rheinheimer, C., Kohl, J., Bautsch, W., and Klos, A. (1999). “Modulation of C3a activity: internalization of the human C3a receptor and its inhibition by C5a.” J.Immunol. 162:7409-7416.PubMedGoogle Scholar
  88. Siciliano, S. J., Rollins, T. E., DeMartino, J., Konteatis, Z., Malkowitz, L., Van Riper, G., Bondy, S., Rosen, H., and Springer, M. S. (1994). “Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors.” Proc.Natl.Acad.Sci.U.S.A. 91:1214-1218.PubMedCrossRefGoogle Scholar
  89. Sniderman, A. D., Cianflone, K., Summers, L., Fielding, B., and Frayn, K. (1997). “The acylation-stimulating protein pathway and regulation of postprandial metabolism.” Proc.Nutr.Soc. 56:703-712.PubMedCrossRefGoogle Scholar
  90. Stahel, P. F., Frei, K., Eugster, H. P., Fontana, A., Hummel, K. M., Wetsel, R. A., Ames, R. S., and Barnum, S. R. (1997). “TNF-alpha-mediated expression of the receptor for anaphylatoxin C5a on neurons in experimental Listeria meningoencephalitis.” J.Immunol. 159:861-869.PubMedGoogle Scholar
  91. Tao, Y., Cianflone, K., Sniderman, A. D., Colby-Germinario, S. P., and Germinario, R. J. (1997). “Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line.” Biochim.Biophys.Acta. 1344:221-229.PubMedGoogle Scholar
  92. Townson, J. R. and Nibbs, R. J. (2002). “Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR.” Eur.J.Immunol. 32:1230-1241.PubMedCrossRefGoogle Scholar
  93. Weselake, R. J., Kazala, E. C., Cianflone, K., Boehr, D. D., Middleton, C. K., Rennie, C. D., Laroche, A., and Recnik, I. (2000). “Human acylation stimulating protein enhances triacylglycerol biosynthesis in plant microsomes.” FEBS Lett. 481:189-192.PubMedCrossRefGoogle Scholar
  94. Wetsel, R. A. (1995). “Expression of the complement C5a anaphylatoxin receptor (C5aR) on non- myeloid cells.” Immunol.Lett. 44:183-187.PubMedCrossRefGoogle Scholar
  95. Wetsel, R. A., Kildsgaard, J., Zsigmond, E., Liao, W., and Chan, L. (1999). “Genetic deficiency of acylation stimulating protein (ASP(C3ades-Arg)) does not cause hyperapobetalipoproteinemia in mice.” J.Biol.Chem. 274:19429-19433.PubMedCrossRefGoogle Scholar
  96. Wilken, H. C., Gotze, O., Werfel, T., and Zwirner, J. (1999). “C3a(desArg) does not bind to and signal through the human C3a receptor.” Immunol.Lett. 67:141-145.PubMedCrossRefGoogle Scholar
  97. Xia, Z., Sniderman, A. D., and Cianflone, K. (2002). “Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice.” J.Biol.Chem. 277: 45874-45879.PubMedCrossRefGoogle Scholar
  98. Xia, Z., Stanhope, K. L., Digitale, E., Simion, O. M., Chen, L., Havel, P., and Cianflone, K. (2004). “Acylation-stimulating protein (ASP)/complement C3adesArg deficiency results in increased energy expenditure in mice.” J.Biol.Chem. 279:4051-4057.PubMedCrossRefGoogle Scholar
  99. Ylitalo, K., Pajukanta, P., Meri, S., Cantor, R. M., Mero-Matikainen, N., Vakkilainen, J., Nuotio, I., and Taskinen, M. R. (2001). “Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia.” Arterioscler.Thromb.Vasc.Biol. 21:838-843.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Kay Johswich
    • 1
  • Andreas Klos
    • 1
  1. 1.Department of Medical MicrobiologyMedical School Hannover30625 HannoverGermany

Personalised recommendations